Association of Radiomic Features with Genomic Signatures in Thyroid Cancer: a Systematic Review

Overview

Journal J Transl Med

Publisher Biomed Central

Specialties Biomedical Engineering
General Medicine

Date 2024 Nov 30

PMID 39616372

Authors

Neila Luciano

Francesca Maria Orlandella

Mariantonia Braile

Carlo Cavaliere

Marco Aiello

Monica Franzese

Giuliana Salvatore

Affiliations

Soon will be listed here.

Abstract

Background: There is a growing interest on the association of radiomic features with genomic signatures in oncology. Using computational methods, quantitative radiomic data are extracted from various imaging techniques and integrated with genomic information to construct predictive models aimed at advancing diagnostic strategies in cancer patient management. In this context, the aim of this systematic review was to assess the current knowledge on potential application of this association in patients with thyroid cancer (TC).

Methods: A comprehensive literature review was conducted by querying three different databases (PubMed, Scopus and Embase) to identify studies published until June 2024, focusing on the potential association of radiomics and genomics in patients with TC. Pertinent data were subsequently extracted, and the methodological quality was evaluated using the A MeaSurement Tool to Assess Systematic Reviews 2 (AMSTAR 2).

Results: From the initial analysis, a total of 853 papers were identified. After removing duplicates and applying eligibility criteria, we ultimately evaluated 7 articles. It was observed that the most commonly utilized imaging technique for TC examination was ultrasound (US), followed by computed tomography and magnetic resonance imaging. Regarding genomic techniques, sequencing and polymerase chain reaction were the most commonly employed methods to validate genetic alterations. The association of radiomic features with genomic signatures demonstrated promising performance in predicting metastasis to the cervical lymph nodes or RET/PTC rearrangements. The effectiveness of models based on US-radiomic features in predicting BRAF mutation in patients with TC requires further investigation.

Conclusion: Although this systematic review has several limitations, primarily related to the limited amount of available literature data, the association of radiomic features with genomic signatures demonstrates a potential as non-invasive tool to enhance the accuracy and efficacy of TC diagnosis and prognosis. PROSPERO registration number: CRD42024572292.

References

Wang Y, Xu F, Agyekum E, Xiang H, Wang Y, Zhang J . Radiomic Model for Determining the Value of Elasticity and Grayscale Ultrasound Diagnoses for Predicting BRAF Mutations in Papillary Thyroid Carcinoma. Front Endocrinol (Lausanne). 2022; 13:872153. PMC: 9074386. DOI: 10.3389/fendo.2022.872153. View

Howell G, Hodak S, Yip L . RAS mutations in thyroid cancer. Oncologist. 2013; 18(8):926-32. PMC: 3755930. DOI: 10.1634/theoncologist.2013-0072. View

Li S, Zhou B . A review of radiomics and genomics applications in cancers: the way towards precision medicine. Radiat Oncol. 2022; 17(1):217. PMC: 9801589. DOI: 10.1186/s13014-022-02192-2. View

Grieco M, Santoro M, Berlingieri M, Melillo R, Donghi R, Bongarzone I . PTC is a novel rearranged form of the ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas. Cell. 1990; 60(4):557-63. DOI: 10.1016/0092-8674(90)90659-3. View

Tong Y, Sun P, Yong J, Zhang H, Huang Y, Guo Y . Radiogenomic Analysis of Papillary Thyroid Carcinoma for Prediction of Cervical Lymph Node Metastasis: A Preliminary Study. Front Oncol. 2021; 11:682998. PMC: 8276635. DOI: 10.3389/fonc.2021.682998. View

Landa I, Cabanillas M . Genomic alterations in thyroid cancer: biological and clinical insights. Nat Rev Endocrinol. 2023; 20(2):93-110. DOI: 10.1038/s41574-023-00920-6. View

Sakorafas G, Sampanis D, Safioleas M . Cervical lymph node dissection in papillary thyroid cancer: current trends, persisting controversies, and unclarified uncertainties. Surg Oncol. 2009; 19(2):e57-70. DOI: 10.1016/j.suronc.2009.04.002. View

Bi W, Hosny A, Schabath M, Giger M, Birkbak N, Mehrtash A . Artificial intelligence in cancer imaging: Clinical challenges and applications. CA Cancer J Clin. 2019; 69(2):127-157. PMC: 6403009. DOI: 10.3322/caac.21552. View

Schlumberger M, Leboulleux S . Current practice in patients with differentiated thyroid cancer. Nat Rev Endocrinol. 2020; 17(3):176-188. DOI: 10.1038/s41574-020-00448-z. View

10.

. Integrated genomic characterization of papillary thyroid carcinoma. Cell. 2014; 159(3):676-90. PMC: 4243044. DOI: 10.1016/j.cell.2014.09.050. View

11.

Bellini D, Milan M, Bordin A, Rizzi R, Rengo M, Vicini S . A Focus on the Synergy of Radiomics and RNA Sequencing in Breast Cancer. Int J Mol Sci. 2023; 24(8). PMC: 10138689. DOI: 10.3390/ijms24087214. View

12.

Incoronato M, Aiello M, Infante T, Cavaliere C, Grimaldi A, Mirabelli P . Radiogenomic Analysis of Oncological Data: A Technical Survey. Int J Mol Sci. 2017; 18(4). PMC: 5412389. DOI: 10.3390/ijms18040805. View

13.

Zheng T, Hu W, Wang H, Xie X, Tang L, Liu W . MRI-Based Texture Analysis for Preoperative Prediction of BRAF V600E Mutation in Papillary Thyroid Carcinoma. J Multidiscip Healthc. 2023; 16:1-10. PMC: 9831001. DOI: 10.2147/JMDH.S393993. View

14.

Zhao C, Zheng J, Sun L, Xu R, Wei Q, Xu H . BRAF mutation analysis in fine-needle aspiration cytology specimens for diagnosis of thyroid nodules: The influence of false-positive and false-negative results. Cancer Med. 2019; 8(12):5577-5589. PMC: 6745841. DOI: 10.1002/cam4.2478. View

15.

Zhang R, Hu L, Cheng Y, Chang L, Dong L, Han L . Targeted sequencing of DNA/RNA combined with radiomics predicts lymph node metastasis of papillary thyroid carcinoma. Cancer Imaging. 2024; 24(1):75. PMC: 11181663. DOI: 10.1186/s40644-024-00719-2. View

16.

Gillies R, Kinahan P, Hricak H . Radiomics: Images Are More than Pictures, They Are Data. Radiology. 2015; 278(2):563-77. PMC: 4734157. DOI: 10.1148/radiol.2015151169. View

17.

Pinker K, Shitano F, Sala E, Do R, Young R, Wibmer A . Background, current role, and potential applications of radiogenomics. J Magn Reson Imaging. 2017; 47(3):604-620. PMC: 5916793. DOI: 10.1002/jmri.25870. View

18.

Fagin J, Krishnamoorthy G, Landa I . Pathogenesis of cancers derived from thyroid follicular cells. Nat Rev Cancer. 2023; 23(9):631-650. PMC: 10763075. DOI: 10.1038/s41568-023-00598-y. View

19.

Stang A . Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010; 25(9):603-5. DOI: 10.1007/s10654-010-9491-z. View

20.

Busaidy N, Konda B, Wei L, Wirth L, Devine C, Daniels G . Dabrafenib Versus Dabrafenib + Trametinib in -Mutated Radioactive Iodine Refractory Differentiated Thyroid Cancer: Results of a Randomized, Phase 2, Open-Label Multicenter Trial. Thyroid. 2022; 32(10):1184-1192. PMC: 9595631. DOI: 10.1089/thy.2022.0115. View